For IC definition

For IC. For Collaborator (if separate from above): Technology Transfer Manager for Finances Same as above. NCI, Technology Transfer Center 9609 Medical Center Dr., 1E-452, MSC 9702 Bxxxxxxx, XX 00000-0000 Tel: 200-000-0000 Email: Bxxxxx.Xxxxxxxxxxx@xxx.xxx EIN: 50-0000000 Delivery of Materials Identified in Appendix B (if any) For IC: Jxx X. Xxxxxxxxx, M.D., Ph.D. Chief, NCI CCR Vaccine Branch Bxxx. 00—Rm D702D (MSC-5062) National Institutes of Health 40 Xxxxxxx Xxxxx Xxxxxxxx, Xxxxxxxx 00000-0000 XXX Tel: 200-000-0000 Fax: 200-000-0000 Email: bxxxxxxx@xxxx.xxx.xxx For Collaborator: Wxxxxxx X. Xxxxxxxx, M.D. BriaCell Therapeutics Corp. 800 Xxxxx Xxxxxx Xxxxxxxx, XX 00000 Office: 1- 000-000-0000 Cell: 1- 000-000-0000 Fax: 1- 000-000-0000 Email: wxxxxxxx@XxxxXxxx.xxx PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, RELEASE THIS SUMMARY PAGE TO THE PUBLIC. TITLE OF CRADA: Evaluation of BriaCell Therapeutics Corp.’s proprietary Bria-OTS cellular immunotherapy using dendritic cell lines as vehicles for cancer vaccines IC Component: National Cancer Institute IC Principal Investigator: Jxx Xxxxxxxxx, M.D., Ph.D. Collaborator: BriaCell Therapeutics Corp. Collaborator Principal Investigator: Wxxxxxx X. Xxxxxxxx, M.D. TERM OF CRADA: Three (3) years from the Effective Date. ABSTRACT OF THE RESEARCH PLAN: The National Cancer Institute and BriaCell Therapeutics Corp. will work together to conduct preclinical studies under a Cooperative Research and Development Agreement (CRADA) to develop and test BriaCell Therapeutic Corp.’s proprietary Bria-OTS cellular immunotherapy as a treatment for cancer to improve and broaden applicability of this therapeutic strategy. PHS CRADAPage 18 of 27 Agreement Ref. No. 03363Confidential MODEL ADOPTED June 18, 2009Revised August 1, 2012 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT APPENDIX A RESEARCH PLAN GOAL AND SCOPE OF THIS CRADA The principal goal of this CRADA is to evaluate the use of BriaCell Therapeutic Corp.’s (BriaCell) proprietary Bria-OTS cellular immunotherapy as a treatment for cancer to improve and broaden the applicability of this therapeutic strategy. More specifically, using BriaCell’s proprietary Bria-OTS cellular immunotherapy, the NCI Vaccine Branch (VB) and BriaCell researchers will develop and test allogeneic, immortalized mouse and potentially human dendritic cells (DCs) that express select sets of mouse...
Sample 1
For IC. For Collaborator (same as above) Technology Transfer CenterNational Cancer Xxxxxxxxx0000 Xxxxxxx Xxxxxx XxxxxXxxxxxxx, XX 00000-0000 MSC 9702Rockville, MD 00000-0000 (express mail)Tel: [***]Fax: [***]
Sample 1
For IC. For Collaborator: Xxxxxx X. Xxxxxxxxx, M.D., Xx.X.Xxxxxxx Branch, NCI10 Center Drive, MSC 1201Bldg. 10, CRC Xxxx 0-0000Xxxxxxxx, XX 00000-0000Xxx. [***]Fax: [***] and [***] Xxxx Xxxxxxx, Ph.D.Vice President, Research &DevelopmentAlaunos Therapeutics, Inc.8020 El RioHouston TX 77030Email: [***]
Sample 1

Examples of For IC in a sentence

  • No. 00-0-00000 Page 30 of 33 Confidential CONTACTS INFORMATION PAGE CRADA Notices For IC: Xxxxxx X.

  • No. 03363Confidential MODEL ADOPTED June 18, 2009Revised August 1, 2012 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT CONTACTS INFORMATION PAGE CRADA Notices For IC: Technology Transfer Center National Cancer Institute 9000 Xxxxxxx Xxxxxx Xxxxx Xxxxxxxx, XX 00000-0000 MXX 0000 Rxxxxxxxx, XX 00000-0000 (express mail) Tel: 200-000-0000/Fax: 200-000-0000 For Collaborator: Wxxxxxx X.

  • No. NIAAA 01638 MODEL ADOPTED June 18, 2009 Public Health Service Cooperative Research and Development Agreement CONTACTS INFORMATION PAGE CRADA Notices For IC: For Collaborator: Gxxxxx Xxxxx, MD, PhD Mxxxxx Xxxxxx NIAAA, 5000 Xxxxxxx Xxxx, Xx. 2S24 Vital Spark, Inc.

  • For IC: For Collaborator: Technology Transfer Manager for FinancesNCI, Technology Transfer Xxxxxx0000 Xxxxxxx Xxxxxx Xx., 0X-000, XXX0000Xxxxxxxx, XX 00000-0000Xxx: [***]Email: [***]EIN: 52-085811 Xxxxxxxxx LegalSr. Manager, Accounts Xxxxxxx0000 Xx Xxx Xx.Xxxxxxx XX 00000[***] Delivery of Materials Identified in Appendix B (if any) For IC: For Collaborator: Xxxxxx X.

  • The Issuer shall also deliver a copy of the Change of Control Issuer Notice to the Trustee and the Paying Agent at such time as it is mailed to Holders of Notes.

  • Public Health Service Cooperative Research and Development Agreement CONTACTS INFORMATION PAGE CRADA Notices For IC: For Collaborator: Gxxxxx Xxxxx, MD, PhD Mxxxxx Xxxxxx NIAAA, 5000 Xxxxxxx Xxxx, Xx. 2S24 Vital Spark, Inc.

  • Xxxxxxxx 00, Xxxx X000X 000 Xxxxxxx Xxx Xxxxxxxx, XX 00000 Xxxxx Xxxxxxxxx, XX 00000 Tel: (000) 000-0000 Tel: Fax: (000) 000-0000 Fax: Email: xxxxxx@xxxx.xxx.xxx Email: xxxxx@xxxxxxxxxx.xxx Clinical Contact (as needed for Article 4.4.2) For IC: Xxxxxx X.

  • CONTACTS INFORMATION PAGE CRADA Notices For IC: For Collaborator: [ * ] [ * ] Patenting and Licensing For IC: For Collaborator (if separate from above): [ * ] [ * ] Delivery of Materials Identified In Appendix B (if any) For IC: For Collaborator: N/A N/A PHS ECT-CRADA Case Ref.


More Definitions of For IC

For IC. For Collaborator: Director, Office of Technology Transfer & Xxx Xxxxx Development, NIDDK President 00 Xxxxx Xxxxx (Xxxx 00X) Xxxx 0000 Xxxxxxxx, XX 00000-0000 Raptor Therapeutics, Inc. 0 Xxxxxxxxxx Xxxx., Xxxxx 000 T: (301) 451-3636Novato XX 00000 XXX@xxxxx.xxx.xxx T: (415) 382-8111 ext. 227 xxxxxx@xxxxxxxxxxxx.xxx With a copy to: Xxxxxxx X. Xxxxx Attorney, Xxxxxx Xxxxxxx Xxxxxxxx and Xxxxxx PC 000 Xxxx Xxxx Xxxx Xxxx Xxxx, XX 00000 xxxxxx@xxxx.xxx Patenting and Licensing For IC: For Collaborator (if separate from above): Division Director Division of Technology Development and Transfer NIH Office of Technology Transfer 0000 Xxxxxxxxx Xxxxxxxxx, Xxxxx 000 Xxxxxxxxx, Xxxxxxxx 00000-0000 Tel: 000-000-0000 Fax: 000-000-0000 IC Project Officer for Extramural Investigators Name: Xxxxxx Doo, MD Title: Director, Liver Diseases Program Division: Division of Digestive and Liver Diseases, NIDDK Address: 0000 Xxxxxxxxx Xxxx., Xxxx 000 Xxxxxxxx, XX 00000-0000 Telephone 000-000-0000 Email: xx00x@xxx.xxx [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of this offer letter which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. SUMMARY PAGE EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, RELEASE THIS SUMMARY PAGE TO THE PUBLIC.
Sample 1

Related to For IC

  • Cell means a single encased electrochemical unit containing one positive and one negative electrode which exhibits a voltage differential across its two terminals.

  • WITNESSED BY By: /s/S. Xxxx Xxxx By: /s/Xxxxx Xxxxxx --------------- --------------- Xxxxx Xxxxxx Treasurer First Financial Fund, Inc. The High Yield Plus Fund, Inc.

  • Protector means a utility-owned electrical device located in the central office, at a customer’s premises or anywhere along any telephone facilities which protects both the telephone utility’s and the customer’s property and facilities from over-voltage and over-current by shunting such excessive voltage and currents to ground.

  • Preschool means a program licensed to offer early childhood services, which follows a preschool curriculum and course of study designed primarily to enhance the educational development of the children enrolled and which serves no child for more than three hours per day.

  • Adolescent means a Medicaid patient 17 years or younger.

  • Check 21 means the Check Clearing for the 21st Century Act.

  • Embryo or "fetus" means the developing human organism from conception until time of birth.

  • Midwife means a midwife in good standing with the College of Midwives of Ontario;

  • Seed means seed in the botanical sense other than seed not intended for planting;